FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas.
1p19q
CGP
F1CDx
FoundationOne
comprehensive genomic profiling
glioma
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
Molecular profiling of gliomas is vital to ensure diagnostic accuracy, inform prognosis, and identify clinical trial options for primary and recurrent tumors. This study aimed to determine the accuracy of reporting the whole arm 1p19q codeletion status from the FoundationOne platform. Testing was performed on glioma samples as part of clinical care and analyzed up to 395 cancer-associated genes (including Concordance between 1p19q status based on FISH and our algorithm was 96.7% (449/463) with a positive predictive value (PPV) of 100% and a positive percent agreement (PPA) of 91.0%. All discordant samples were positive for codeletion by FISH and harbored genomic alterations inconsistent with oligodendrogliomas. Median overall survival was 168 months for the 1p19q codeletion status derived from FoundationOne testing is highly concordant with FISH results. Genomic profiling may be a reliable substitute for traditional FISH testing while also providing
Sections du résumé
BACKGROUND
BACKGROUND
Molecular profiling of gliomas is vital to ensure diagnostic accuracy, inform prognosis, and identify clinical trial options for primary and recurrent tumors. This study aimed to determine the accuracy of reporting the whole arm 1p19q codeletion status from the FoundationOne platform.
METHODS
METHODS
Testing was performed on glioma samples as part of clinical care and analyzed up to 395 cancer-associated genes (including
RESULTS
RESULTS
Concordance between 1p19q status based on FISH and our algorithm was 96.7% (449/463) with a positive predictive value (PPV) of 100% and a positive percent agreement (PPA) of 91.0%. All discordant samples were positive for codeletion by FISH and harbored genomic alterations inconsistent with oligodendrogliomas. Median overall survival was 168 months for the
CONCLUSIONS
CONCLUSIONS
1p19q codeletion status derived from FoundationOne testing is highly concordant with FISH results. Genomic profiling may be a reliable substitute for traditional FISH testing while also providing
Identifiants
pubmed: 33778493
doi: 10.1093/noajnl/vdab017
pii: vdab017
pmc: PMC7986056
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdab017Subventions
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
J Clin Oncol. 2006 Jun 20;24(18):2707-14
pubmed: 16782910
Brain Pathol. 2008 Jul;18(3):360-9
pubmed: 18371182
Neuro Oncol. 2010 Jul;12(7):664-78
pubmed: 20164239
Oncotarget. 2015 Oct 6;6(30):30295-305
pubmed: 26210286
J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345
pubmed: 29118226
PLoS Comput Biol. 2018 Feb 7;14(2):e1005965
pubmed: 29415044
J Clin Oncol. 2000 Feb;18(3):636-45
pubmed: 10653879
J Clin Oncol. 2013 Jan 20;31(3):328-36
pubmed: 23269986
Neurology. 2010 Jun 8;74(23):1886-90
pubmed: 20427748
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104
pubmed: 9329453
Acta Neuropathol. 2007 Nov;114(5):443-58
pubmed: 17805551
Annu Rev Pathol. 2006;1:97-117
pubmed: 18039109
Mod Pathol. 2015 Feb;28(2):177-86
pubmed: 25081751
Semin Radiat Oncol. 2015 Jul;25(3):155-63
pubmed: 26050585
Trends Cancer. 2016 Jul;2(7):338-349
pubmed: 28603776
Clin Oncol (R Coll Radiol). 2015 Aug;27(8):445-53
pubmed: 25971646
Front Oncol. 2019 May 17;9:417
pubmed: 31165048
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
pubmed: 9776413
Neuropathol Appl Neurobiol. 2013 Oct;39(6):706-17
pubmed: 23363074
Acta Neurochir (Wien). 2017 Mar;159(3):403-418
pubmed: 28093610
J Neuropathol Exp Neurol. 2012 Jul;71(7):618-24
pubmed: 22710961
Oncotarget. 2014 Sep 30;5(18):8083-92
pubmed: 25257301
Nature. 2020 Apr;580(7804):517-523
pubmed: 32322066
Cancer. 2005 Oct 15;104(8):1693-9
pubmed: 16116609
Neurooncol Adv. 2020 Aug 27;2(1):vdaa109
pubmed: 33205043
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Cancer Res. 2006 Oct 15;66(20):9852-61
pubmed: 17047046
Acta Neuropathol. 2015 Jan;129(1):133-46
pubmed: 25427834